Travere Therapeutics enters the week of October 29 earnings with an uncomfortable gap between where analysts think the stock should trade and where it actually is — and short sellers showing no sign of walking away.
The stock closed at $60.28 on Tuesday, down 4.1% on the day and off 8.3% over the past month. That slide has pushed it meaningfully below a Street consensus target of roughly $75, implying more than 24% upside on paper. Yet the analyst community remained conspicuously static this week: Wedbush and HC Wainwright both reiterated their bullish calls on September 22 without moving their targets. The real target-lifting happened in early August, when a wave of upgrades — Evercore ISI Group, Citigroup, Guggenheim, TD Cowen, and Canaccord Genuity all raised numbers following what appears to have been a strong quarterly print — pushed consensus materially higher. Since then, the stock has given back a chunk of those post-earnings gains. The price-to-earnings multiple has compressed roughly 14% over 30 days to 13.1x, and price-to-book has fallen by a similar magnitude to 11.2x. Valuation is re-rating lower even as analysts hold their targets.
Short interest adds another layer to the tension. Bears hold 13.4% of the free float short — a genuinely elevated position that has edged up roughly 3% over the past month. The ORTEX short score has drifted toward 57 from the mid-56s in early September, suggesting incrementally more bearish signal from the data. Days-to-cover stands at 9.6 per the most recent FINRA filing, a figure that would make a sharp covering rally genuinely disruptive if sentiment shifted. Against that, the borrow market tells a very different story: availability is extremely loose at 2,535%, meaning there are roughly 25 shares available to borrow for every one already borrowed. Cost to borrow is a negligible 0.48%. There is no squeeze pressure in the lending market whatsoever. Bears can add to positions cheaply and easily, which likely explains why short interest has been able to drift higher without any friction.
The bull case from Travere's own data centres on sparsentan's pipeline momentum. The drug is in late-stage development for FSGS and IgAN, two rare kidney disorders with limited treatment options, and patient enrolment reportedly progressed well in Q2 2026. Bulls also point to pegtibatinase, the investigational enzyme replacement therapy for HCU, as a potential second revenue driver. The bear case is less about the science and more about execution: the company has missed earnings expectations, faces capital intensity inherent to rare-disease development, and competes against better-resourced peers. The stock's EPS surprise score sits in just the 4th percentile — a stark number that captures a history of not delivering on the bottom line, even as revenue growth has been strong.
The insider data from last week merits a note of caution before over-interpreting it. The CEO and Chief Commercial Officer both exercised options and sold shares on September 16-17, generating sales of roughly $13 million in aggregate. All transactions were pre-declared under 10b5-1 plans, meaning they were scheduled months in advance and reflect compensation mechanics rather than fresh conviction. These are not discretionary sales. The 90-day net across insiders is a negative $58.6 million in value terms, but most of that figure is driven by the same planned exercise-and-sell activity. No open-market buying has appeared in the recent record.
Institutional ownership is broadly constructive. Janus Henderson holds 12% of shares and added to its position last quarter. BlackRock and Fidelity (FMR LLC) each hold above 6%, and both added shares in the August reporting period. The activist register carries no 13D filers — all major holders are on 13G passive schedules — though the disclosed positions are as-last-filed and may not reflect current levels precisely. Peer correlated names RVMD and BNTC both slipped on the week, while VIR and IRWD moved sharply higher, suggesting the sector backdrop is mixed rather than uniformly weak.
The October 29 earnings print is now the fulcrum — with the stock down on the month, short interest still substantial, and analysts holding targets well above the current price, the Q3 report is less about whether the sparsentan programme is progressing and more about whether Travere can demonstrate that the August enthusiasm translated into commercial and operational execution.
See the live data behind this article on ORTEX.
Open TVTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
